Challenges in the discovery and development of new agents for the treatment of obesity.
New pharmacologic agents are being sought to help manage the epidemic of obesity and its consequences. Understanding the challenges of the history of obesity drugs is wise before investing in new obesity agents. Expectations of patients, physicians, and drug company executives are not consistent with characteristics of current agents or most potential new ones. Owing to the complex biology underlying body weight regulation, combinations of agents may be necessary to improve weight loss efficacy.
Staten
M A
MA
Division of Diabetes and Kidney and Digestive Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. statenm@niddk.nih.gov
D000818:Animals; D019440:Anti-Obesity Agents / Q000266:history / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D049673:History, 20th Century; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
D019440:Anti-Obesity Agents